Mizuho Securities analyst Ann Hynes reiterated a Hold rating on IQVIA Holdings Inc (NYSE: IQV) yesterday and set a price target of $120. The company’s shares closed yesterday at $122.16, close to its 52-week high of $125.35.
According to TipRanks.com, Hynes is a 3-star analyst with an average return of 4.1% and a 55.6% success rate. Hynes covers the Services sector, focusing on stocks such as Encompass Health Corporation, Walgreens Boots Alliance, and Quest Diagnostics Inc.
Currently, the analyst consensus on IQVIA Holdings Inc is a Strong Buy with an average price target of $130.27, representing a 6.6% upside. In a report issued on July 24, Piper Jaffray also reiterated a Hold rating on the stock with a $97 price target.
.
See today’s analyst top recommended stocks >>
Based on IQVIA Holdings Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $2.57 billion and net profit of $61 million. In comparison, last year the company earned revenue of $2.38 billion and had a net profit of $75 million.
Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
IQVIA Holdings, Inc. is a biotechnology company, which engages in healthcare development in the provision of professional services, information technology, and partnering solutions to the pharmaceutical services and healthcare industries. The company was founded by Dennis Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.
